While CANARY prognosis categories did not differ significantly between tumors with EGFR and KRAS mutations (p = 0.16, p = 0.06, respectively), we found that an increase of the V-I-R-O or a decrease of the Y-P component (which is negatively correlated with V-I-R-O correlation = −0.78) within a tumor was associated with a lower likelihood of EGFR positivity (p = 0.01 for V-I-R-O (area under the curve (AUC) = 0.70), p = 0.02 for Y-P (AUC = 0.68)). The gene discussed is KRAS; the disease is neoplasm.